A new national trial is recruiting people with rare autoimmune diseases to measure their COVID-19 antibody response following at least 3 vaccinations.
The MELODY study is recruiting immunocompromised people to determine the antibody levels they develop in response to COVID-19 vaccination.
The MELODY study aims to:
- Assess how many immunocompromised people have detectable antibodies against COVID-19 following at least 3 vaccines;
- Investigate whether a lack of detectable antibodies is associated with risk of infection over a 6-month period;
- Investigate what factors are associated with lack of detectable antibodies in immunocompromised people.
Within MELODY, researchers are particularly focused upon whether specific immunosuppressant medications can change an individual’s immune response to COVID-19 and its vaccinations.
The researchers responsible for MELODY have 36,000 home test kits available. Individuals will be randomly selected and contacted by the study organisers directly.
Participation is very simple – just two online questionnaires and a finger-prick blood test which will allow your antibody levels to be tested. All can be done from the comfort of your own home.
If you would like to read any additional information on this study, the full details can be found on The MELODY study homepage.
This study is being run by doctors at Imperial College London, with support from the following organisations: NHS Digital, NHS Blood and Transplant, University of Southampton, University of Cambridge, University of Nottingham, and Ipsos (an independent research organisation).